Fysiologföreningen: Adrian Newman-Tancredi
The novel pharmacology of antipsychotics: how recent advances point to a key role for serotonin 5-HT1A receptors
Dr. Adrian Newman-Tancredi is a neuropharmacologist with two decades of achievement in industrial "drug hunting". Adrian personally participated in the identification and characterization of novel antipsychotics, antidepressants and analgesics at the Servier Research Institute (Paris, France; 1993-2002) and at Pierre Fabre Laboratories (Castres, France; 2002-2010). In 2010, he created an independent neuropharmacology consulting service (NeuroAct Communication) and then co-founded Neurolixis in 2011, a neuroscience-focused bioscience company. He has published extensive analyses of the mechanism of action of antipsychotic drugs and developed the concept of biased receptors agonists with focus on the 5-HT1A receptor. Use of such biased agonists in conjunction with antipsychotic drugs offers a new strategy for treating schizophrenia patients which is now being explored.
Host: Prof. Sven Ove Ögren